Discover a new frontier in cancer treatment with GoPath Diagnostics' cutting-edge Triplet Testing Approach. Our comprehensive suite of tests includes Germline Testing (GENETICSNOW® Series), Somatic Testing (OncoTarget® 500), and ctDNA Testing (OncoTracking™). Together, these tests provide a holistic view of the genomic landscape, empowering oncologists and patients to make informed decisions for personalized cancer care.
Germline Testing - GENETICSNOW® Series
Uncover Genetic Clues to Tailor Treatment and Assess Risk
Germline Testing (GeneticsNow Series) identifies hereditary gene mutations that can impact cancer treatment options and assess the risk of developing future cancers. By analyzing an individual's inherited genetic makeup, we gain insights into their unique predispositions and potential response to targeted therapies. Our advanced testing methods ensure accurate and reliable results, guiding oncologists in designing personalized treatment plans.
Prostate Cancer 23 Gene Panel + SNP, Genetic Risk Score
Panel details: ABRAXAS1, ATM, ATR, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, FANCA, GEN1, HOXB13, HSD3B1, MLH1, MRE11A, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53, SNP-BASED GRS Average TAT: 10-14 days CPT Code(s): 81162/81163/81164/ (81162, 81405, 81479) depending on insurance Specimen Requirements: 3-5 mL PB in EDTA or preserved saliva Methodology: NGS Disease Group: Prostate
BRCANOW®
Specimen
Order collection kit
Breast and Ovarian Cancer BRCA1/2 del/dup analysis
Average TAT: 14 days CPT Code(s): 81162 Specimen Requirements: 3-5 mL PB in EDTA or preserved saliva Methodology: NGS Disease Group: Breast and Ovarian
BRCANOW® Extended
Specimen
Order collection kit
Breast and Ovarian Cancer 30 Gene Panel
Panel details: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CDK12, CDKN2A, CHEK1, CHEK2, EPCAM, FANCA, FANCL, MLH1, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, PTEN, RAD50, RAD51B, RAD51C, RAD51D, RAD54L, SLX4,STK11, TP53 Average TAT: 14 days CPT Code(s): 81162 Specimen Requirements: 3-5 mL PB in EDTA or preserved saliva Methodology: NGS Disease Group: Breast and Ovarian
LYNCHNOW®
Order collection kit
Colorectal Cancer 5 Gene Panel (MLH1, MSH2, MSH6, PMS2, EPCAM)
Panel details: MLH1, MSH2, MSH6, PMS2, EPCAM Average TAT: 14 days CPT Code(s): 81292, 81295, 81298, 81317 Specimen Requirements: 3-5 mL PB in EDTA or preserved saliva Methodology: NGS Disease Group: Colorectal
LYNCHNOW® Extended
Order collection kit
Colorectal Cancer 32 Gene Panel
Panel details: APC, ATM, AXIN2, BLM, BMPR1A, BRCA1, BRCA2, BUB1B, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, EXO1, FLCN, GREM1, MLH1, MLH3, MSH2, MSH6, MUTYH, NF2, PMS1, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TGFBR2, TP53, VHL Average TAT: 14 days CPT Code(s): 81292, 81295, 81298, 81317/81479 Methodology: NGS Specimen Requirements: 3-5 mL PB in EDTA or preserved saliva Disease Group: Colorectal
16 Gene Panel: ABCC8, APPL1, CEL, GATA4, GCK, HNF1A, HNF1B, HNF4A, INS, KCNJ11, MT-TE m.14709T>C, MT-TL1 m.3243A>G, NEUROD1, PDX1, RFX6, WFS1 Average TAT: 14 days CPT Code(s): 81479 Methodology: NGS Specimen Requirements: 3-5 mL PB in EDTA or preserved saliva Disease Group: Diabetes
Somatic Testing - OncoTarget® 500
Precision Medicine for Targeted Cancer Treatment
Helps oncologists identify specific mutations that drive the tumor growth and select targeted therapies with higher efficacy. By uncovering the genetic drivers of cancer, we empower oncologists to tailor treatment regimens that maximize therapeutic benefits while minimizing side effects.
Real-Time Monitoring for Treatment Response and Minimal Residual Disease
OncoTracking leverages ctDNA Testing, a non-invasive method for monitoring cancer progression and treatment response. We can detect residual disease and track genomic changes over time by analyzing cell-free tumor DNA circulating in the bloodstream. This invaluable tool enables oncologists to make timely adjustments to treatment plans, optimizing patient outcomes and improving survival rates.